3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine | 311332-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine
• CAS: 311332-81-7
• 化学式: C₂₈H₃₄N₂O₂
• 分子量: 430.59
• InChiKey: AOEKOLJMPMENRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  24.9
• 氢给体数：
  0
• 氢受体数：
  4

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  米帕明	impramine	50-49-7	C19H24N2	280.413
  地昔帕明	Desipramin	50-47-5	C18H22N2	266.386

反应信息

• 作为产物：
  描述：

  米帕明 在 正丁基锂 、 1,8-双二甲氨基萘 作用下， 以 四氢呋喃 、 正己烷 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 4.0h， 生成 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine
  参考文献：
  名称：

  NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation

  摘要：

  Ceramide generation is involved in signal transduction of cellular stress response, in particular during stress-induced apoptosis in response to stimuli such as minimally modified Low-density lipoproteins, TNFalpha and exogenous C-6-ceramide. In this paper we describe 48 diverse synthetic products and evaluate their lysosomotropic and acid sphingomyelinase inhibiting activities in macrophages. A stimuli induced increase of C-16-ceramide in macrophages can be almost completely suppressed by representative compound NB 06 providing an effective protection of macrophages against apoptosis. Compounds like NB 06 thus offer highly interesting fields of application besides prevention of apoptosis of macrophages in atherosclerotic plaques in vessel walls. Most importantly, they can be used for blocking pH dependent lysosomal processes and enzymes in general as well as for analyzing lysosomal dependent cellular signaling. Modulation of gene expression of several prominent inflammatory messengers IL1B, IL6, IL23A, CCL4 and CCL20 further indicate potentially beneficial effects in the field of (systemic) infections involving bacterial endotoxins like LPS or infections with influenza A virus. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.09.021

文献信息

• SPHINGOMYELINASE INHIBITOREN ALS WIRKSTOFFE MIT ANTIAPOPTOTISCHER UND ANTISEPTISCHER WIRKUNG
  申请人：Biofrontera Pharmaceuticals GmbH

  公开号：EP1207886B1

  公开（公告）日：2005-11-16
• G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1603874A2

  公开（公告）日：2005-12-14
• COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS
  申请人：Salvemini Daniela

  公开号：US20100086543A1

  公开（公告）日：2010-04-08

  Provided are a pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor and a pharmaceutically acceptable carrier. The method of treatment involves administration of an opioid drug and a ceramide biosynthesis inhibitor. Also provided are a method of screening for an agent that reduces, prevents or delays the development of tolerance to and/or physical dependence on an opioid drug as well as compositions comprising a dsRNA for inhibiting ceramide biosynthesis in a cell and a vector for expressing a shRNA for inhibiting ceramide biosynthesis in a cell.
• Compositions and Methods for Treating Pulmonary Conditions
  申请人：Vij Neeraj

  公开号：US20130131146A1

  公开（公告）日：2013-05-23

  The present invention relates to the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary conditions. In one embodiment, a method for assessing the severity of lung damage from a pulmonary condition in a subject comprises the steps of (a) measuring the level and/or functional activity of membrane/lipid-raft cystic fibrosis transmembrane conductance regulator (CFTR)in a sample from the subject; (b) measuring the level of ceramide or its species in a sample from the subject; and (c) comparing the membrane/lipid- raft CFTR level and/or functional activity and ceramide level to a control sample, wherein a difference in membrane/lipid-raft CFTR level and/or functional activity and ceramide level is indicative of the severity of lung damage. The method can further comprise treating the subject based on the severity of lung damage. In particular embodiments, the treatment comprises administering a CFTR agonist and/or an agent that inhibits the synthesis of ccramide or its species.
• [EN] G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS<br/>[FR] DERIVES DE LA G-LACTAME UTILISES COMME AGONISTES DE LA PROSTAGLANDINE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2004078103A2

  公开（公告）日：2004-09-16

  The present invention relates Ϝ-lactam derivatives, within the definitions of A, B, D, E, G, J, K, L, M, and N according to claims 1, in particular for use as medicaments, as well as pharmaceutical formulations containing such Ϝ-lactam derivatives. Said Ϝ-lactam derivatives are useful in the treatment and/or prevention of asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders of Formula (I).